Tirzepatide

Plain English Interpretation

This research explains how tirzepatide works at the molecular level. It mainly activates the GIP receptor strongly but only partly activates the GLP-1 receptor, and it prefers certain signaling pathways over others. This unique activity may help explain why tirzepatide is effective in lowering blood sugar and reducing weight. It also shows that tirzepatide affects the receptors differently, internalizing GIP receptors fully but only partially affecting GLP-1 receptors. These findings help us understand how tirzepatide improves metabolic health and can guide the development of future treatments.

Scientific Findings

Using human adipocyte and mouse models, we investigated how long-acting GIPR agonists regulate fasted and fed adipocyte functions. In functional assays, GIPR agonism enhanced insulin signaling, augmented glucose uptake, and increased the conversion of glucose to glycerol in a cooperative manner with insulin; however, in the absence of insulin, GIPR agonists increased lipolysis. In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased. Our findings support a model for long-acting GIPR agonists to modulate both fasted and fed adipose tissue function differentially by cooperating with insulin to augment glucose and lipid clearance in the fed state while enhancing lipid release when insulin levels are reduced in the fasted state.